AbbVie is a research-based biopharmaceutical company focused on developing and marketing innovative therapies in several key therapeutic areas including immunology, oncology, neuroscience, and ophthalmology.
AbbVie, a prominent United States-based pharmaceutical company, was the issuer of a specific fixed-income instrument, identified by ISIN US00287YBC21 and CUSIP 00287YBC2, which has since matured and been fully redeemed on November 13, 2023, at its par value of 100%. This USD-denominated bond carried an annual interest rate of 3.75% and was part of a significant issuance totaling $1,250,000,000, with a minimum purchase amount of $2,000 and interest payments occurring semi-annually. Throughout its lifecycle, the bond maintained investment-grade credit ratings of BBB+ from Standard & Poor's and Baa2 from Moody's.
|